메뉴 건너뛰기




Volumn 45, Issue 6, 2010, Pages 670-677

An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma

Author keywords

5 FU; APCI; Capecitabine; Clinical routine; LC MS MS

Indexed keywords

5-FLUOROURACIL (5-FU); ACTIVE METABOLITES; ANTICANCER DRUG; ASSAY METHODS; ATMOSPHERE PRESSURE; BLOOD SAMPLES; CALIBRATION CURVES; CAPECITABINE; CHEMICAL IONIZATION; CHROMATOGRAPHIC SEPARATIONS; CLINICAL ROUTINE; COST-EFFECTIVE METHODS; DRUG CONCENTRATION; EX-VIVO; FOOD AND DRUG ADMINISTRATION; HUMAN PLASMAS; INTER-ASSAY PRECISION; INTERNAL STANDARDS; ISOTOPIC DERIVATIVES; LABORATORY PRACTICES; LC/MS-MS; LIQUID-LIQUID EXTRACTION; MATRIX EFFECTS; REVERSE-PHASE COLUMN; STANDARD SAMPLES; THERAPEUTIC DRUG MONITORING; TREATMENT FAILURE;

EID: 77953169731     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1759     Document Type: Article
Times cited : (38)

References (27)
  • 1
    • 33745927137 scopus 로고    scopus 로고
    • How may anticancer chemotherapy with fluorouracil be individualised?
    • S. A. Ploylearmsaeng, U. Fuhr, A. Jetter. How may anticancer chemotherapy with fluorouracil be individualised? Clin. Pharmacokinet. 2006, 45, 567.
    • (2006) Clin. Pharmacokinet. , vol.45 , pp. 567
    • Ploylearmsaeng, S.A.1    Fuhr, U.2    Jetter, A.3
  • 2
    • 0032978473 scopus 로고    scopus 로고
    • Can pharmacokinetic monitoring improve clinical use of fluorouracil?
    • A. M. Young, S. Daryanani, D. J. Kerr. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clin.Pharmacokinet. 1999, 36, 391.
    • (1999) Clin.Pharmacokinet. , vol.36 , pp. 391
    • Young, A.M.1    Daryanani, S.2    Kerr, D.J.3
  • 3
    • 0031790577 scopus 로고    scopus 로고
    • The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology
    • R. B. Diasio. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Williston Park) 1998, 12, 23.
    • (1998) Oncology (Williston Park) , vol.12 , pp. 23
    • Diasio, R.B.1
  • 4
    • 14844303761 scopus 로고    scopus 로고
    • Capecitabine: A review
    • C. M. Walko, C. Lindley. Capecitabine: a review. Clin. Ther. 2005, 27, 23.
    • (2005) Clin. Ther. , vol.27 , pp. 23
    • Walko, C.M.1    Lindley, C.2
  • 5
    • 0032127244 scopus 로고    scopus 로고
    • Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
    • M. Miwa, M. Ura, M. Nishida, N. Sawada, T. Ishikawa, K. Mori, N. Shimma, I. Umeda, H. Ishitsuka. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 1998, 34, 1274.
    • (1998) Eur. J. Cancer , vol.34 , pp. 1274
    • Miwa, M.1    Ura, M.2    Nishida, M.3    Sawada, N.4    Ishikawa, T.5    Mori, K.6    Shimma, N.7    Umeda, I.8    Ishitsuka, H.9
  • 6
    • 33947301765 scopus 로고    scopus 로고
    • Capecitabine: In advanced gastric or oesophagogastric cancer
    • S. Dhillon, L. J. Scott. Capecitabine: in advanced gastric or oesophagogastric cancer. Drugs 2007, 67, 601.
    • (2007) Drugs , vol.67 , pp. 601
    • Dhillon, S.1    Scott, L.J.2
  • 10
    • 0031890613 scopus 로고    scopus 로고
    • Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis
    • M. C. Etienne, E. Chatelut, X. Pivot, M. Lavit, A. Pujol, P. Canal, G. Milano. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur. J. Cancer 1998, 34, 92.
    • (1998) Eur. J. Cancer , vol.34 , pp. 92
    • Etienne, M.C.1    Chatelut, E.2    Pivot, X.3    Lavit, M.4    Pujol, A.5    Canal, P.6    Milano, G.7
  • 11
    • 0031696544 scopus 로고    scopus 로고
    • Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: Results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas
    • R. Fety, F. Rolland, M. Barberi-Heyob, A. Hardouin, L. Campion, T. Conroy, J. L. Merlin, A. Riviere, G. Perrocheau, M. C. Etienne, G. Milano. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin. Cancer Res. 1998, 4, 2039.
    • (1998) Clin. Cancer Res. , vol.4 , pp. 2039
    • Fety, R.1    Rolland, F.2    Barberi-Heyob, M.3    Hardouin, A.4    Campion, L.5    Conroy, T.6    Merlin, J.L.7    Riviere, A.8    Perrocheau, G.9    Etienne, M.C.10    Milano, G.11
  • 15
    • 0024512054 scopus 로고
    • 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
    • J. Santini, G. Milano, A. Thyss, N. Renee, P. Viens, P. Ayela, M. Schneider, F. Demard. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br. J. Cancer 1989, 59, 287.
    • (1989) Br. J. Cancer , vol.59 , pp. 287
    • Santini, J.1    Milano, G.2    Thyss, A.3    Renee, N.4    Viens, P.5    Ayela, P.6    Schneider, M.7    Demard, F.8
  • 17
    • 0003484310 scopus 로고    scopus 로고
    • FDA. Center for Drug Evaluation and Research. Food and Drug Administration
    • FDA. Guidance for Industry. Bioanalytical Method Validation. In: Center for Drug Evaluation and Research. Food and Drug Administration, 2001.
    • (2001) Guidance for Industry. Bioanalytical Method Validation
  • 18
    • 0032986050 scopus 로고    scopus 로고
    • The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds
    • R. Bonfiglio, R. C. King, T. V. Olah, K. Merkle. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999, 13, 1175.
    • (1999) Rapid Commun. Mass Spectrom. , vol.13 , pp. 1175
    • Bonfiglio, R.1    King, R.C.2    Olah, T.V.3    Merkle, K.4
  • 19
    • 30444448196 scopus 로고    scopus 로고
    • Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis
    • B. K. Matuszewski. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 830, 293.
    • (2006) J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. , vol.830 , pp. 293
    • Matuszewski, B.K.1
  • 20
    • 77953350741 scopus 로고    scopus 로고
    • Signal suppression/enhancement in high-performance liquid chromatography tandem mass spectrometry
    • DOI: 10.1016/j.chroma.2009.11.060
    • F.Gosetti, E.Mazzucco, D.Zampieri, M.C.Gennaro. Signal suppression/enhancement in high-performance liquid chromatography tandem mass spectrometry. J. Chromatogr. A 2009, DOI: 10.1016/j.chroma.2009.11.060.
    • (2009) J. Chromatogr. A
    • Gosetti, F.1    Mazzucco, E.2    Zampieri, D.3    Gennaro, M.C.4
  • 21
    • 0038574979 scopus 로고    scopus 로고
    • Ion suppression in mass spectrometry
    • T. M. Annesley. Ion suppression in mass spectrometry. Clin. Chem. 2003, 49, 1041.
    • (2003) Clin. Chem. , vol.49 , pp. 1041
    • Annesley, T.M.1
  • 22
    • 58149112644 scopus 로고    scopus 로고
    • Effect of eluent on the ionization process in liquid chromatography-mass spectrometry
    • R. Kostiainen, T. J. Kauppila. Effect of eluent on the ionization process in liquid chromatography-mass spectrometry. J. Chromatogr. A 2009, 1216, 685.
    • (2009) J. Chromatogr. A , vol.1216 , pp. 685
    • Kostiainen, R.1    Kauppila, T.J.2
  • 23
    • 26844581328 scopus 로고    scopus 로고
    • Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies
    • S.M. Guichard, I.Mayer, D. I. Jodrell. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 826, 232.
    • (2005) J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. , vol.826 , pp. 232
    • Guichard, S.M.1    Mayer, I.2    Jodrell, D.I.3
  • 24
    • 0032940053 scopus 로고    scopus 로고
    • Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
    • E. Gamelin, M. Boisdron-Celle, V. Guerin-Meyer, R. Delva, A. Lortholary, F. Genevieve, F. Larra, N. Ifrah, J. Robert. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol. 1999, 17, 1105.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 1105
    • Gamelin, E.1    Boisdron-Celle, M.2    Guerin-Meyer, V.3    Delva, R.4    Lortholary, A.5    Genevieve, F.6    Larra, F.7    Ifrah, N.8    Robert, J.9
  • 26
    • 77950204871 scopus 로고    scopus 로고
    • A new, validated HPLC-MS/MS method for thesimultaneous determination of the anti-cancer agent capecitabine and itsmetabolites: 5′-deoxy-5- fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma
    • L. D. Vainchtein, H. Rosing, J. H. Schellens, J. H. Beijnen. A new, validated HPLC-MS/MS method for thesimultaneous determination of the anti-cancer agent capecitabine and itsmetabolites: 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomed. Chromatogr. 2010, 24, 374.
    • (2010) Biomed. Chromatogr. , vol.24 , pp. 374
    • Vainchtein, L.D.1    Rosing, H.2    Schellens, J.H.3    Beijnen, J.H.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.